Adverum Biotechnologies, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ADVM Nasdaq 2830 adverum.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Adverum Biotechnologies, Inc.

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 6th, 2024 9:05 pm
Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Nov 20th, 2024 9:05 pm
Adverum Reports Positive Ixo-vec Data for Wet Age-Related Macular Degeneration; Shares Rise Pre-Bell - Nov 18th, 2024 1:16 pm
Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements - Nov 18th, 2024 12:00 pm
Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements - Nov 15th, 2024 9:05 pm
Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates - Nov 4th, 2024 11:00 pm
Adverum Biotechnologies: Q3 Earnings Snapshot - Nov 4th, 2024 10:06 pm
Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones - Nov 4th, 2024 9:39 pm
Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program - Oct 16th, 2024 12:00 pm
Adverum Biotechnologies (ADVM) Upgraded to Strong Buy: What Does It Mean for the Stock? - Oct 11th, 2024 4:00 pm
Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic - Oct 3rd, 2024 9:17 am
Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences - Sep 4th, 2024 8:05 pm
Wall Street Analysts See a 332.28% Upside in Adverum Biotechnologies (ADVM): Can the Stock Really Move This High? - Sep 3rd, 2024 1:55 pm
Adverum Biotechnologies: Q2 Earnings Snapshot - Aug 12th, 2024 8:35 pm
Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate Highlights - Aug 12th, 2024 8:05 pm
Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference - Aug 2nd, 2024 11:00 am
Adverum Biotechnologies Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted for Ixo-vec for the Treatment of Wet AMD - Aug 1st, 2024 12:00 pm
Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year? - Jul 18th, 2024 1:40 pm
Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting - Jul 17th, 2024 6:45 am
Wall Street Analysts Think Adverum Biotechnologies (ADVM) Could Surge 290.54%: Read This Before Placing a Bet - Jul 16th, 2024 1:55 pm